Angiogenic inhibitor pre‐administration improves the therapeutic effects of immunotherapy

Angiogenic inhibitor pre‐administration improves the therapeutic effects of immunotherapy

Abstract In lung cancer, immune checkpoint inhibitors (ICIs) are often inadequate for tumor growth inhibition. Angiogenic inhibitors (AIs) are required to normalize tumor vasculature for improved immune cell infiltration. However, in clinical practice, ICIs and cytotoxic antineoplastic agents are si...

Full description

Bibliographic Details
Main Authors: Mineyoshi Sato, Nako Maishi, Yasuhiro Hida, Aya Yanagawa‐Matsuda, Mohammad Towfik Alam, Jun Sakakibara‐Konishi, Jin‐Min Nam, Yasuhito Onodera, Satoshi Konno, Kyoko Hida
Format: Article
Language:English
Published: Wiley 2023-04-01
Series:Cancer Medicine
Subjects:
angiogenesis inhibitors
immune checkpoint inhibitors
immunotherapy
lung neoplasms
tumor microenvironment
Online Access:https://doi.org/10.1002/cam4.5696

Internet

https://doi.org/10.1002/cam4.5696

Similar Items